Effects of High-Dose Resveratrol in Non-Diabetic Obese Males
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02247596|
Recruitment Status : Completed
First Posted : September 25, 2014
Last Update Posted : September 25, 2014
|Condition or disease||Intervention/treatment||Phase|
|Obesity Diabetes||Drug: Resveratrol Drug: Placebo||Phase 2|
Patients were recruited between July 2009 and July 2012 from a single hospital in Singapore. Eligible patients were Chinese males, aged between 21 and 55 years old, with a body mass index (BMI) of 30 kg/m2 or more and venous glucose of <7.0 and <11.1 mmol/L at 0 and 120 minutes respectively on oral glucose tolerance testing (OGTT) following a 12-hour fast. They must be willing to abstain from embarking on an exercise regime or ingesting large quantities of resveratrol-containing foods including alcohol during the study period.
The study was a randomized, double-blind, parallel group trial consisting of a screening visit, a two-week treatment period and a post-treatment visit.
Randomization was centrally performed during treatment assignment with a 2-digit reference code placed in sealed opaque envelopes maintained by the person responsible for the preparation of the intervention drug and placebo. Trans-resveratrol extract from Polygonum Cuspidatum (Mega Resveratrol, Danbury, USA) was used in the trial. The placebo was not distinguishable by color, form, or taste from the active drug. The randomization code was unblinded only after all predefined data were recorded.
Subjects were given 1g three times a day of either resveratrol or placebo for two weeks and instructed to abstain from foods with high resveratrol content during the entire duration of the trial. Compliance was determined by pill counting at the end of the trial period. Subjects in both arms were not allowed to commence on an exercise regimen or supplements during the study period. Subjects who dropped out of the trial would not be replaced. All variables were measured at baseline and at the end of the treatment period.
RMR was measured by indirect calorimetry using a breath-by-breath metabolic gas analyser via the face-mask method.
The investigators estimated that a sample size of 18 patients per group (Total N = 36) was needed to provide 80% power and two-sided 5% to detect a difference in a Cohen's effect size of 1.0 between the two groups.
All analyses were performed using SPSS 21.0 (IBM) with statistical significance set at p < 0.05 and with the percentage change from baseline as the unit of analysis. All data were analyzed according to the intention-to-treat principle. MANOVA was performed to compare the intervention and placebo groups for the unadjusted and adjusted p-values on the study variables of interest. Normal distribution was verified with the Kolmogorov-Smirnov test and data were presented as mean ± standard deviation (SD).
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||36 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Effects of High-Dose Resveratrol on Resting Energy Expenditure and HOMA in Non-Diabetic Obese Males|
|Study Start Date :||July 2009|
|Actual Primary Completion Date :||October 2012|
|Actual Study Completion Date :||October 2012|
Placebo Comparator: Placebo
Sugar pill 1g tds for 2 weeks
Sugar pill 1g tds for 2 weeks
Trans-resveratrol extract from Polygonum Cuspidatum 1g three times a day for 2 weeks
1g tds 2 weeks
Other Name: Mega Resveratrol
- Change from baseline in Resting Energy Expenditure via indirect calorimetry at 2 weeks [ Time Frame: 2 weeks (pre and post intervention) ]Measured in Kcal/day using a metabolic cart
- Change from baseline in insulin resistance via Homeostasis Model Assessment (HOMA) 2 calculator at 2 weeks [ Time Frame: 2 weeks (pre and post intervention) ]Beta cell function, B (%),Insulin sensitivity, S (%), Insulin resistance, IR
- Change from baseline in lipid subfractions at 2 weeks [ Time Frame: 2 weeks (pre and post intervention) ]LDL, HDL and triglycerides in mmol/L
- Change from baseline in Blood pressure at 2 weeks [ Time Frame: 2 weeks (pre and post intervention) ]Systolic and diastolic blood pressure in mmHg
- Change from baseline in Glycated hemoglobin at 2 weeks [ Time Frame: 2 weeks (pre and post intervention) ]HbA1c in %
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02247596
|Khoo Teck Puat Hospital|
|Singapore, Singapore, 768828|
|Principal Investigator:||Kian Peng Goh||Khoo Teck Puat Hospital|